Market Information

Curated by: Johanna FIHMAN

A World Health Organization (WHO) initiative, Market Information for Access to Vaccines (MI4A), has been launched to contribute to the achievement of Strategic Development Goal 3.8 (Universal Health Coverage target) by enhancing access to safe, effective, quality, and affordable vaccines for all. It is a part of the broader WHO effort to ensure availability of Essential Medicines and responds to specific requests from Member States and the WHO Strategic Advisory Group of Experts on Immunization (SAGE) to address vaccine market information gaps.

Building on existing efforts, MI4A provides a global perspective on vaccine markets, responding to WHA Resolutions and WHO SAGE requests for action. In particular, MI4A aims to identify and address affordability and shortage issues for self-funding and self-procuring countries that are mostly excluded from international support. MI4A leverages the success of the WHO Vaccine Product, Price and Procurement (V3P) project. Middle-income countries (MICs) face the greatest challenge of ensuring sustainable access to vaccine supply, given their limited external assistance and national resources. Further information relating to MICs, including the Strategy to Enhance Immunization in MICs, can be found on WHO’s website.

This page, created and maintained by the WHO Expanded Programme on Immunization (EPI), provides a list of key MI4A resources, grouped into the following categories:

The MI4A Resource Gateway also provides links to relevant WHO and partner websites - including PAHO, PATH and UNICEF - that contain information about vaccine product characteristics, vaccine price and procurement information.


What data is available?

The WHO vaccine market intelligence database compiles vaccine purchase (product, price and procurement) data as reported by countries via the WHO/UNICEF Joint Reporting Form (JRF) over the period of 2013–2018. Data is shared by country, vaccine and year. Price per dose (USD), procurement mechanism and annual volumes are all included, and data is publicly available on the MI4A website.

Countries can use the vaccine purchase data in different ways, such as to:

  • Understand how the price of vaccines in their immunization schedule relate to other products on the market, or compare the prices paid by other countries in similar conditions (e.g. income, funding/procurement group, contract conditions) – for example: how much does seasonal flu cost in countries similar to mine?
  • Identify other vaccines available by a given manufacturer – e.g., what products are in the portfolio of a manufacturer of interest for my country?
  • Understand other available products and presentations for each vaccine – e.g., what BCG vaccine products are on the market?
  • Develop budget estimates to inform new vaccine introduction product choices, planning and budgeting.


What resources are available?

  • Vaccine Purchase Data Note: This cover note is intended to guide countries in their use of the MI4A vaccine purchase data and includes key messages from the global analysis.
  • Available products list: A list of all available vaccine products, including WHO prequalified and non WHO prequalified vaccines.
  • Global Vaccine Market Report: This report provides a snapshot of the global vaccine market covering all vaccines and countries. The report is divided into five sections: 1. vaccine market transparency, 2. global vaccine market value and volume, 3. vaccine products, 4. vaccine procurement and 5. vaccine price.
  • Global market studies: MI4A produces vaccine-specific market studies, analysing global demand and supply prospects for individual vaccines. The studies identify areas of risk for sustainable access to vaccine supply and define mitigating actions. Market studies are available for BCG, D&T, HPV, and Meningococcal Meningitis. Key findings are also available for PCV and Rota.


 About MI4A


Vaccine purchase data 


Market studies 

MI4A produces a range of market analyses and vaccine-specific reports. These aim to strengthen understanding of global vaccine supply-demand dynamics, identifying affordability and shortage risks.